Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Oncology Consultations®: Critical Conversations for Treating sAML in the Outpatient Setting

Release Date: December 8, 2021
Expiration Date: December 8, 2022

Activity Overview

This online, on-demand virtual program brings together 2 experts to discuss how they have integrated new diagnostic tools and acute myeloid leukemia (AML) therapies into their treatment algorithms for patients with secondary AML (sAML). Since 2017, 9 new agents have been approved for the treatment of AML, including FLT3 inhibitors, IDH inhibitors, a liposomal formulation of cytarabine-daunorubicin, and a BCL-2 inhibitor, among others. In their conversation, the faculty review recent efficacy and safety data regarding these therapies and discuss the caveats associated with treating this specific group of patients. They discuss 3 real-world cases of patients with secondary AML with a focus on management in the outpatient setting.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is intended for community oncologists and hematologists who treat patients with AML. Researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with AML are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Discuss clinical and logistical challenges related to sAML care and potential advantages of outpatient management for these patients
  • Utilize clinical, cytogenetic, genomic, and molecular information to facilitate early identification and risk stratification among patients with secondary AML (sAML)
  • Review evolving sAML treatment strategies, including how patient- and tumor-specific features can inform decision-making in the context of outpatient care approaches

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.


Jorge Cortes, MD
Jorge Cortes, MD
Director, Georgia Cancer Center
Professor of Medicine
Augusta University
Augusta, GA

Disclosures: Grant/Research Support: Pfizer, Jazz Pharmaceuticals, AbbVie, Novartis; Consultant: Pfizer, Jazz Pharmaceuticals, Novartis.
Yehuda Deutsch, MD
Yehuda Deutsch, MD
Assistant Member, Department of Malignant Hematology and Cellular Therapy
Moffitt Malignant Hematology & Cellular Therapy
Memorial Healthcare System
Memorial Cancer Institute
Pembroke Pines, FL

Disclosures: Yehuda Deutsch, MD, has no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By